心不全治療薬の考え方、使い方　改訂2版

出版社： 中外医学社
著者：
発行日： 2023-10-20
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784498136595
電子書籍版： 2023-10-20 （2版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,280 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,280 円(税込)

購入する

商品紹介

複雑な心不全治療薬の使い方について，エビデンスを中心に整理することはもちろん，同系薬剤の使い分けや未知の事柄についても追記した超実践的な書の改訂版．ARNIやSGLT2阻害薬の躍進，ベルイシグアトの登場，さらには成人先天性心疾患合併や免疫抑制療法など，心不全診療を巡る話題を網羅した内容となっている．またコラムも刷新し，読み応えも十分．U40心不全ネットワークの新世代による心不全治療薬のスタンダードをぜひご覧ください．

目次

  • 1章　心不全治療薬の考え方，使い方概論
    　A．心不全の薬剤使用総
    　　
    2章　基本薬
    　1．β遮断薬
    　　A．β遮断薬の作用機序
    　　B．β遮断薬を心不全症例に使用する目的
    　　C．β遮断薬の心不全症例における有効性を示すエビデンス
    　　D．β遮断薬を使用する際の注意点
    　　E．同系薬剤の使い分け
    　　F．β遮断薬の未知
    　2．ACE阻害薬
    　　A．作用機序
    　　B．心不全患者に使用する目的
    　　C．心不全患者における有用性を示すエビデンス
    　　D．使用する際の注意点（副作用，漸増の仕方，中止の判断など）
    　　E．同系薬剤の使い分けについて
    　　F．ACE阻害薬に対する未知
    　3．ARNI（Sacubitril／Valsartan）
    　　A．作用機序
    　　B．心不全患者に使用する目的
    　　C．心不全患者における有用性を示すエビデンス
    　　D．使用する際の注意点（副作用，漸増の仕方，中止の判断など）
    　　E．同系薬剤の使い分けについて
    　　F．ARNIに関する未知
    　4．ミネラルコルチコイド受容体
    　　A．作用機序
    　　B．心不全患者に使用する目的
    　　C．心不全患者における有用性を示すエビデンス
    　　D．使用する際の注意点（副作用，漸増の仕方，中止の判断など）
    　　E．同系薬剤の使い分けについて
    　　F．同薬剤に関する未知
    　5．SGLT2阻害薬
    　　A．作用機序
    　　B．心不全患者に使用する目的
    　　C．心不全患者における有用性を示すエビデンス
    　　D．使用する際の注意点
    　　E．使い分けについて
    　　F．今後の展望
    　　G．キーとなる臨床試験のまとめ
    　　
    3章　利尿薬
    　1．ループ利尿薬
    　　A．ループ利尿薬の作用機序
    　　B．ループ利尿薬を心不全患者に使用する目的
    　　C．ループ利尿薬の心不全患者における有用性を示すエビデンス
    　　D．使用する際の注意点（副作用，漸増の仕方，中止の判断など）
    　　E．ループ利尿薬の使い分けについて
    　　F．ループ利尿薬に関する未知
    　2．サイアザイド系利尿薬
    　　A．サイアザイド系利尿薬の作用機序
    　　B．サイアザイド系利尿薬を心不全患者に使用する目的
    　　C．サイアザイド系利尿薬の心不全患者における有用性を示すエビデンス
    　　D．使用する際の注意点（副作用，漸増の仕方，中止の判断など）
    　　E．サイアザイド系利尿薬の使い分けについて
    　　F．サイアザイド系利尿薬に関する未知
    　3．トルバプタン　〈生駒剛典　末永祐哉〉
    　　A．トルバプタンの作用機序
    　　B．トルバプタンを心不全患者に使用する目的
    　　C．トルバプタンの心不全患者における有用性を示すエビデンス
    　　D．トルバプタンを使用する際の注意点
    　　E．同系薬剤の使い分け
    　　F．トルバプタンに関する未知
    　4．利尿薬抵抗性に対する対応　〈石原里美　末永祐哉〉
    　　A．心不全治療におけるうっ血管理の重要性
    　　B．利尿薬抵抗性の機序
    　　C．利尿薬抵抗性への対応
    　　D．ultrafiltration
    　　
    4章　強心薬
    　1．ドブタミン
    　　A．ドブタミンの作用機序
    　　B．ドブタミンを心不全患者に使用する目的
    　　C．ドブタミンの心不全患者における有用性を示すエビデンス
    　　D．使用する際の注意点　副作用・漸減・漸増・中止の判断
    　　E．同系薬剤との使い分けについて
    　　F．ドブタミンに関する未知
    　2．PDE—III阻害薬
    　　A．PDE—III阻害薬の作用機序
    　　B．各国ガイドラインのPDE—III阻害薬の適応
    　　C．PDE—III阻害薬のエビデンス
    　　D．PDE—III阻害薬の投与方法と注意点
    　　E．同系薬剤の使い分け，ドブタミンとの併用療法
    　　F．PDE—III阻害薬に関する未知
    　3．経口強心薬
    　　A．経口強心薬の作用機序
    　　B．経口強心薬の使用目的
    　　C．経口強心薬のエビデンス
    　　D．経口強心薬を使用する際の注意点
    　4．その他（ドパミン，ノルアドレナリン，血管収縮薬など）
    　　A．作用機序
    　　B．使用目的
    　　C．使い分け
    　　D．注意点
    　　E．未知
    　5．強心薬開始の基準，漸減の仕方，その際のチェック項目
    　6．移植申請のタイミング，機械的補助循環（MCS）と薬剤併用
    　　A．MCSの種類と特徴
    　　B．MCSサポート下での薬剤使用
    　　C．MCS導入後のストラテジー
    　　D．MCSからの離脱
    　　
    5章　血管拡張薬
    　1．硝酸薬とCa拮抗薬の違いと使い分け
    　　A．硝酸薬
    　　B．静注Ca拮抗薬
    　2．カルペリチド
    　　A．作用機序
    　　B．心不全患者に投与する目的
    　　C．有用性を示すエビデンス
    　　D．使用する際の注意点（初期投与量，副作用，終了判断など）
    　　E．同系薬剤の使い分けについて
    　　F．カルペリチドに関する未知
    　3．ニコランジル
    　　A．ニコランジルの作用機序および虚血性心疾患への適応
    　　B．心不全患者に対する使用目的およびそのエビデンス
    　　C．心不全に使用する際の注意点
    　　D．硝酸薬との使い分け
    　　E．ニコランジルに関する未知
    　4．血管拡張薬の考え方，使い方
    　　A．急性心不全患者における血管拡張薬使用の現状
    　　B．血管拡張薬の血行動態への影響を考える
    　　C．血管拡張薬のエビデンス
    　　D．急性心不全患者に対する血管拡張薬投与の実際
    　　E．急性心不全患者に対する新規血管拡張薬
    　　
    6章　抗不整脈薬
    　1．アミオダロン
    　　A．アミオダロンの作用機序
    　　B．アミオダロンの心不全患者への使用目的
    　　C．アミオダロンの心不全患者へのエビデンス
    　　D．使用する際の注意（副作用や漸減方法，中止の判断など）
    　　E．同系統薬の使い分けについて
    　　F．アミオダロンの未知
    　2．心不全管理における至適心拍数の考え方と薬剤使用
    　　A．レートコントロールとリズムコントロール
    　　B．レートコントロールに使用する薬剤
    　　C．至適心拍数とは
    　　
    7章　心不全に併発した心房細動に対する抗凝固薬
    　A．作用機序
    　B．心不全患者に使用する目的
    　C．心不全患者における有用性を示すエビデンス
    　D．使用する際の注意点・具体的な使用方法
    　E．薬剤の使い分け
    　F．今後の展望・未知
    　
    8章　その他の薬剤
    　1．ジゴキシン
    　　A．薬剤の作用機序
    　　B．心不全患者に使用する目的
    　　C．心不全患者におけるエビデンス
    　　D．使用する際の注意点
    　　E．薬剤の使い分けについて
    　　F．薬剤に関する未知
    　2．イバブラジン
    　　A．作用機序
    　　B．心不全患者に使用する目的
    　　C．心不全患者における有用性を示すエビデンス
    　　D．使用する際の注意
    　　E．今後の展望
    　3．ベルイシグアト
    　　A．作用機序
    　　B．心不全患者に使用する目的
    　　C．心不全患者における有用性を示すエビデンス
    　　D．使用する際の注意点（副作用，漸減の仕方，中止の判断など）
    　　E．同薬剤の使い分け
    　　F．ベルイシグアトにおける未知
    　4．心筋ミオシン活性化薬
    　　A．作用機序
    　　B．心不全患者に使用する目的
    　　C．心不全患者における有用性を示すエビデンス
    　　D．心筋ミオシン活性化薬に関する未知

    　PV loopから考える薬の考え方，使い方
    　　A．圧容積ループ（pressure volume loop）
    　　B．圧容積ループからわかること
    　　C．心拍出量直線，心拍出量曲線をイメージする
    　　D．循環平衡理論
    　　E．圧容積ループ，循環平衡理論から考える心不全治療薬の効果
    　　
    10章　心不全に合併する電解質異常の治療
    　　A．低Na血症
    　　B．K代謝異常（低K血症／高K血症）
    　　
    11章　心不全に合併する貧血の治療
    　A．心不全と貧血
    　B．心不全と鉄代謝
    　C．鉄補充
    　D．輸血療法
    　E．心腎貧血症候群
    　F．ESA（erythropoiesis stimulating agent）
    　G．HIF—PH（hypoxia—inducible factor—prolyl hydroxylase）
    　
    12章　心不全に合併する高尿酸血症の治療
    　A．高尿酸血症の定義
    　B．高尿酸血症の病型分類と，尿酸降下薬の作用機序
    　C．適応・禁忌，使用するのに注意すべき点，有用な患者・注意すべき患者
    　D．薬剤の心不全患者における代表的なエビデンス（ガイドライン）
    　E．具体的な使用方法
    　
    13章　アドヒアランスを意識した薬剤使用とポリファーマシー
    　1．アドヒアランスを意識した薬剤使用
    　　A．心不全患者と服薬アドヒアランス
    　　B．服薬アドヒアランスを高めるためには？
    　　C．内服薬の管理のしやすさを目指す
    　2．ポリファーマシー
    　　A．ポリファーマシーの定義とその問題点
    　　B．心不全におけるポリファーマシーの実態とその介入法
    　　
    　麻薬，鎮静薬の考え方，使い方と心不全緩和ケア
    　　A．心不全における医療用麻薬の考え方，使い方
    　　B．心不全患者における鎮静薬の考え方，使い方
    　　C．心不全患者に対する緩和ケア
    　　
    15章　成人先天性心疾患患者の心不全
    　A．成人先天性心疾患患者の心不全とその特徴
    　B．心不全をきたす主な先天性疾患とそのポイント
    　C．ACHD合併心不全における薬物療法の立ち位置とその考え方
    　D．ACHD合併心不全におけるSGLT2阻害薬・ARNIの立ち位置
    　E．成人循環器科医としてのACHDにどう携わるべきか？
    　
    16章　心不全における免疫抑制療法
    　A．心筋炎
    　B．心臓サルコイドーシス
    　C．ステロイド・免疫抑制薬の使い方と注意点
    　
    17章　心不全治療薬の投与量と薬物動態

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 心不全治療薬の考え方, 使い方概論

P.22 掲載の参考文献
1) Tsutsui H, Isobe M, Ito H, et al. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure-Digest version-. Circ J. 2019 ; 83 : 2084-184.
PubMed
2) Tsutsui H, Ide T, Ito H, et al. JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. Circ J. 2021 ; 85 : 2252-91.
PubMed
3) Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
4) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 ; 42 : 3599-726.
 
5) McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023 ; ehad195. Online ahead of print.
 
6) Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure : a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure : Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021 ; 23 : 352-80.
 
7) Masip J, Frank Peacok W, Arrigo M, et al. Acute Heart Failure in the 2021 ESC Heart Failure Guidelines : a scientific statement from the Association for Acute Cardio Vascular Care (ACVC) of the European Society of Cardiology. European Heart Journal Acute Cardiovascular Care. 2022 ; 11 : 173-85.
 
8) Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK Stage classification expert consensus update : A review and incorporation of validation studies : This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. J Am Coll Cardiol. 2022 ; 79 : 933-46.
 

2章 基本薬

P.29 掲載の参考文献
1) Packer M, Bristow RM, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996 ; 334 : 1349-55.
 
2) CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : A randomised trial. Lancet. 1999 ; 353 : 9-13.
 
3) MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 ; 353 : 2001-7.
 
4) Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure : Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 ; 106 : 2194-9.
PubMed
5) Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure : The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004 ; 147 : 324-30.
PubMed
6) Okamoto H, Hori M, Matsuzaki M, et al. J-CHF Investigators. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol : Japanese chronic heart failure (J-CHF) study. Int J Cardiol. 2013 ; 164 : 238-44.
PubMed
7) Hori M, Nagai R, Izumi T, et al. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure : results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart FailureII (MAIN-CHFII) study. Heart Vessels. 2014 ; 29 : 238-47.
 
8) The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet. 2001 ; 357 : 1385-90.
PubMed
9) Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 ; 94 : 2807-16.
PubMed
10) 日本循環器学会/日本心不全学会. 急性・慢性心不全診療ガイドライン (2017年改訂版).
Medical*Online
11) Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure. Findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008 ; 52 : 190-9.
PubMed
12) Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF) : an open-label, pilot, randomised trial. Lancet. 2018 ; 6736 : 1-13.
 
13) Dungen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure : The CIBIS-ELD trial. Eur J Heart Fail. 2011 ; 13 : 670-80.
PubMed
14) Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction. Circ J. 2013 ; 77 : 908-16.
PubMed
15) Kotecha D, Holmes J, Krum H, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation : An individual-patient data meta-analysis. Lancet. 2014 ; 384 : 2235-43.
 
16) Kotecha D, Flather MD, Altman DG, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol. 2017 ; 69 : 2885-96.
PubMed
17) Li SJ, Sartipy U, Lund LH, et al. Prognostic significance of resting heart rate and use of β-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction : Findings from the Swedish Heart Failure Registry. Circ Heart Fail. 2015 ; 8 : 871-9.
 
18) Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction : An individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018 ; 39 : 26-35.
PubMed
19) Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction : The Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013 ; 15 : 110-8.
PubMed
20) Lund LH, Benson L, Dahlstrom U, et al. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014 ; 312 : 2008-18.
 
21) Palau P, Seller J, Dominguez E, et al. Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol. 2021 ; 78 : 2042-56.
 
22) Meyer M, Lewinter, MM. Heart rate and heart failure with preserved ejection fraction : Time to slow β-blocker use? Circ Heart Fail. 2019 ; 12 : 1-5.
 
P.37 掲載の参考文献
1) Nehme A, Zouein FA, Zayeri ZD, et al. An update on the tissue renin angiotensin system and its role in physiology and pathology. J Cardiovasc Dev Dis. 2019 ; 6 : 14.
PubMed
2) Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure : randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000 ; 355 : 1582-7.
PubMed
3) Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999 ; 100 : 2312-8.
 
4) CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 ; 316 : 1429-35.
 
5) SOLVD Investigators, Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 ; 325 : 293-302.
PubMed
6) SOLVD Investigators, Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 ; 327 : 685-91.
PubMed
7) Cleland JG, Tendera M, Adamus J, et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006 ; 27 : 2338-45.
 
8) 日本循環器学会. 急性・慢性心不全診療ガイドライン (2017年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf
 
9) Lund LH, Benson L, Dahlstrom U, et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012 ; 308 : 2108-17.
PubMed
10) Hicks BM, Filion KB, Yin H, et al. Angiotensin converting enzyme inhibitors and risk of lung cancer : population based cohort study. BMJ. 2018 ; 363 : k4209.
PubMed
11) Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 ; 325 : 303-10.
PubMed
12) GISSI-3 : effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994 ; 343 : 1115-22.
PubMed
13) Cohn JN, Tognoni G and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 ; 345 : 1667-75.
 
14) ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 : 1547-59.
 
15) Blood Pressure Lowering Treatment Trialists Collaboration, Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007 ; 25 : 951-8.
PubMed
16) Willenheimer R, van Veldhuisen DJ, Silke B, et al. CIBIS Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence : results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005 ; 112 : 2426-35.
PubMed
17) Yancy CW, Januzzi JL, Allen LA, et al. 2017 ACC Expert consensus decision pathway for optimization of heart failure treatment. J Am Coll Cardiol. 2018 ; 71 : 201-30.
PubMed
18) Tsuji K, Sakata Y, Nochioka K, et al. CHART-2 Investigators. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017 ; 19 : 1258-69.
 
19) Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF) : an open-label, pilot, randomised trial. Lancet. 2019 ; 393 : 61-73.
PubMed
20) 2021年JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf
 
21) Hsu CY, Chang HY, Chao CJ, et al. Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan. Front Cardiovasc Med. 2022 ; 9 : 950389.
PubMed
P.46 掲載の参考文献
1) Packer M, McMurray JJ, Desai AS, et al ; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 ; 131 : 54-61.
PubMed
2) Myhre PL, Vaduganathan M, Claggett B, et al. B-Type natriuretic peptide during treatment with sacubitril/valsartan : The PARADIGM-HF Trial. J Am Coll Cardiol. 2019 ; 73 : 1264-72.
 
3) Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibitor in acute decompensated heart failure. N Engl J Med. 2019 ; 380 : 539-48.
PubMed
4) Solomon SD, Vaduganathan M, L Claggett B, et al., Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020 ; 141 : 352-61.
PubMed
5) Vaduganathan M, Claggett BL, Desai AS, et al., Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol. 2020 ; 75 (3) : 245-254.
PubMed
6) Mentz RJ, Ward JH, Hernandez AF, et al., Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023 ; 82 : 1-12.
 
7) Vaduganathan M, Mentz RJ, Claggett BL, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction : a prespecified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023 ; 44 : 2982-93.
PubMed
8) McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 ; 371 : 993-1004.
PubMed
9) Solomon SD, McMurray JJV, Anand IS, et al ; PARAGON-HF Investigators and committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019 ; 381 : 1609-20.
PubMed
10) Vardeny O, Claggett B, Packer M, et al., Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction : PARADIGM-HF trial. Eur J Heart Fail. 2016 ; 18 : 1228-34.
PubMed
11) Pfeffer MA, Claggett B, Lewis EF, et al ; PARADISE-MI Investigators and Committees. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021 ; 385 : 1845-55.
PubMed
12) Mehran R, Steg PG, Pfeffer MA, et al. The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction : Insights From the PARADISE-MI Trial. Circulation. 2022 ; 146 : 1749-57.
PubMed
P.53 掲載の参考文献
1) Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 ; 341 : 709-17.
 
2) Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 ; 364 : 11-21.
 
3) Pitt B, Pfeffer MA, Assmann SF, et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 ; 370 : 1383-92.
PubMed
4) Collins A, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017 ; 46 : 213-21.
PubMed
5) Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021 ; 385 : 2252-63.
PubMed
6) Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020 ; 383 : 2219-29.
PubMed
7) Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease : the FIDELITY pooled analysis. Eur Heart J. 2022 ; 43 : 474-84.
PubMed
8) Butler J, Anker S, Lund L, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction : the DIAMOND trial. Eur Heart J. 2022 ; 43 : 4362-73.
PubMed
P.59 掲載の参考文献
1) Butler J, Hamo CE, Filippatos G, et al ; EMPEROR Trials Program. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017 ; 19 : 1390-400.
 
2) Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001 ; 103 : 2668-73.
PubMed
3) MacDonald MR, Petrie MC, Varyani F, et al ; CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure : an analysis of the Candesartan in Heart failure : Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008 ; 29 : 1377-85.
PubMed
4) Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy : the search for a unifying hypothesis. Circ Res. 2006 ; 98 : 596-605.
PubMed
5) Control Group ; Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009 ; 52 : 2288-98.
PubMed
6) Zinman B, Wanner C, Lachin JM, et al. ; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 ; 373 : 2117-28.
PubMed
7) Neal B, Perkovic V, Mahaffey KW, et al ; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 ; 377 : 644-57.
 
8) Wiviott SD, Raz I, Bonaca MP ; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019 ; 380 : 347-57.
PubMed
9) Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure : Diuretic and cardiorenal effects. Circulation. 2020 ; 142 : 1028-39.
PubMed
10) Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit : a state-of-the-art review. Diabetologia. 2018 ; 61 : 2108-117.
PubMed
11) The EMPA-KIDNEY Collaborative Group ; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023 ; 388 : 117-27.
 
12) Heerspink HJL, Stefansson BV, Correa-Rotter R, et al ; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 ; 383 : 1436-46.
PubMed
13) Honka H, Solis-Herrera C, Triplitt C, et al. Therapeutic manipulation of myocardial metabolism : JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 ; 77 : 2022-39.
PubMed
14) Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019 ; 139 : 2528-36.
PubMed
15) Packer M, Anker SD, Butler J, et al ; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020 ; 383 : 1413-24.
PubMed
16) McMurray JJV, Solomon SD, Inzucchi SE, et al ; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 ; 381 : 1995-2008.
PubMed
17) Anker SD, Butler J, Filippatos G, et al ; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 ; 385 : 1451-61.
PubMed
18) Solomon SD, McMurray JJV, Claggett B, et al ; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022 ; 387 : 1089-98.
 
19) Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure : a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 ; 400 : 757-67.
PubMed
20) Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure : a multinational randomized trial. Nat Med. 2022 ; 28 : 568-74.
PubMed
21) Horiuchi Y, Matsue Y, Nogi K, et al. Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure : Rationale for and design of the EMPA-AHF trial. Am Heart J. 2023 ; 257 : 85-92.
PubMed
22) The EMPA-KIDNEY Collaborative Group ; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023 ; 388 : 117-27.
 
P.63 掲載の参考文献
1) Okura Y, Ramadan MM, Ohno Y, et al. Impending epidemic : future projection of heart failure in Japan to the year 2055. Circ J. 2008 ; 72 : 489-91.
 
2) Taylor RS, Long L, Mordi IR, et al. Exercise-based rehabilitation for heart failure : Cochrane systematic review, meta-analysis, and trial sequential analysis. JACC Heart Fail. 2019 ; 7 : 691-705.
PubMed
3) 日本心臓リハビリテーション学会. 2021年改訂版 心血管疾患におけるリハビリテーションに関するガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Makita.pdf (2021年3月22 日閲覧).
 
4) Kamiya K, Yamamoto T, Tsuchihashi-Makaya M, et al. Nationwide survey of multidisciplinary care and cardiac rehabilitation for patients with heart failure in Japan-An analysis of the AMED-CHF Study-. Circ J. 2019 ; 83 : 1546-52.
PubMed
P.67 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会合同ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版).
 
2) Ferrick AM, Raj SR, Deneke T, et al. 2023 HRS/EHRA/APHRS/LAHRS expert consensus statement on practical management of the remote device clinic. Heart Rhythm. 2023 ; S1547-5271 (23) 02011-8.
 
3) Hajduczok AG, Muallem SN, Nudy MS, et al. Remote monitoring for heart failure using implantable devices : a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Heart Fail Rev. 2022 ; 27 : 1281-300.
PubMed
4) Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF) : a randomised controlled trial. Lancet. 2021 ; 398 : 991-1001.
PubMed
5) Zile MR, Mehra MR, Ducharme A, et al. Hemodynamically-guided management of heart failure across the ejection fraction spectrum : The GUIDE-HF Trial. JACC Heart Fail. 2022 ; 10 : 931-44.
PubMed
6) Tsuchihashi-Makaya M, Matsuo H, Kakinoki S, et al. Home-based disease management program to improve psychological status in patients with heart failure in Japan. Circ J. 2013 ; 77 : 926-33.
PubMed
7) Angermann CE, Stork S, Gelbrich G, et al. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure : the Interdisciplinary Network for Heart Failure (INH) study. Circ Heart Fail. 2012 ; 5 : 25-35.
 
8) Angermann CE, Sehner S, Faller H, et al. Longer-term effects of remote patient management following hospital discharge after acute systolic heart failure : The Randomized E-INH Trial. JACC Heart Fail. 2023 ; 11 : 191-206.
PubMed
9) Kikuchi A, Taniguchi T, Nakamoto K, et al. Feasibility of home-based cardiac rehabilitation using an integrated telerehabilitation platform in elderly patients with heart failure : A pilot study. J Cardiol. 2021 ; 78 : 66-71.
PubMed
10) Chimura M, Koba S, Sakata Y, et al. Evaluation of the efficacy and safety of an integrated telerehabilitation platform for home-based cardiac REHABilitation in patients with heart failure (E-REHAB) : protocol for a randomised controlled trial. BMJ Open. 2023 ; 13 : e073846.
PubMed

3章 利尿薬

P.73 掲載の参考文献
1) Shiraishi Y, Kohsaka S, Sato N, et al. 9-Year trend in the management of acute heart failure in Japan : A report from the national consortium of acute heart failure registries. J Am Heart Assoc. 2018 ; 7 : e008687.
PubMed
2) Matsue Y, Damman K, Yoors AA, et al. Time-to-furosemide treatment and mortality in patient hospitalized with acute heart failure. J Am Coll Cardiol. 2017 ; 69 : 3042-51.
 
3) Shiraishi Y, Kurita Y, Matsukawa M, et al. Real-world intravenous diuretic use to treat congestion in patients with heart failure-An observational study using a research database. Circ Rep. 2023 ; 5 : 27-37.
PubMed
4) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 : 3599-726.
PubMed
5) Drazner MH, Rame JE, Stevensen LW, et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001 ; 345 : 574-81.
 
6) Drazner MH, Rame JE, Dries DL. Third heart sound and elevated jugular venous pressure as markers of the subsequent development of heart failure in patients with asymptomatic left ventricular dysfunction. Am J Med. 2003 ; 114 : 431-7.
PubMed
7) Domanski M, Norman J, Pitt B, et al. Diuretics use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 2003 ; 42 : 705-8.
PubMed
8) Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization : an observational study using propensity score methods. Eur Heart J. 2006 ; 27 : 1431-9.
 
9) Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006 ; 97 : 1759-64.
PubMed
10) Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 ; 364 : 797-805.
PubMed
11) Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017 ; 377 : 1964-75.
PubMed
12) Nunez J, Bayes-Genis A, Zannad F, et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation. 2018 ; 137 : 1320-30.
PubMed
13) Aldahl M, Jensen AC, Davidsen L, et al. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J. 2017 ; 38 : 2890-6.
PubMed
14) Masuyama T, Tsujino T, Origasa H, et al. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J. 2012 ; 76 : 833-42.
PubMed
15) Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001 ; 111 : 513-20.
PubMed
16) DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol. 2012 ; 8 : 707-28.
PubMed
17) Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure : The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023 ; 329 : 214-23.
PubMed
P.78 掲載の参考文献
1) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 ; 288 : 2981-97.
PubMed
2) Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008 ; 358 : 1887-98.
 
3) Tsujimoto T, Kajio H. Thiazide use and decreased risk of heart failure in nondiabetic patients receiving intensive blood pressure treatment. Hypertension. 2020 ; 76 : 432-41.
PubMed
4) Jentzer JC, De Wald TA, Hermendaz AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010 ; 56 : 1527-34.
 
5) Siqurd B, Olesen KH, Wennevold A. The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide. Am Heart J. 1975 ; 89 : 163-70.
 
6) Mehta MH, Rogers JG, Hasselblad V, et al. Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure. Am J Cardiol. 2009 ; 103 : 76-81.
 
7) Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017 ; 377 : 1964-75.
PubMed
8) Salah K, Pinto YM, Eulings LW, et al. Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month morality, independent of N-terminal pro-B-type natriuretic peptide levels : an individual patient data analysis. Am Heart J. 2015 ; 170 : 531-42.e1.
 
9) Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001 ; 96 : 132-43.
PubMed
10) Trulls JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure : the CLOROTIC trial. Eur Heart J. 2023 ; 44 : 411-21.
 
11) Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022 ; 387 : 1185-95.
PubMed
12) Yamazoe M, Mizuno A, Kohsaka S, et al. Incidence of hospital-acquired hyponatremia by the dose and type of diuretics among patients with acute heart failure and its association with long-term outcomes. J Cardiol. 2018 ; 71 : 550-6.
PubMed
13) Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA. 2007 ; 297 : 1319-31.
PubMed
P.84 掲載の参考文献
1) Kinugawa K, Imamura T, Komuro I. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. Clin Pharmacol Ther. 2013 ; 94 : 449-51.
PubMed
2) Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : the EVEREST Clinical Status Trials. JAMA. 2007 ; 297 : 1332-43.
PubMed
3) Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA. 2007 ; 297 : 1319-31.
PubMed
4) Kinugawa K, Matsukawa M, Nakamura Y, et al. Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management : A retrospective cohort study using a medical claim database in Japan. J Cardiol. 2023 ; 82 : 35-42.
PubMed
5) Kawabata H, Iwatani H, Yamamichi Y, et al. Tolvaptan efficiently reduces Intracellular fluid : Working toward a potential treatment option for cellular edema. Intern Med. 2019 ; 58 : 639-42.
 
6) Takagi K, Sato N, Ishihara S, et al. Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure. J Cardiol. 2020 ; 76 : 499-505.
PubMed
7) Shirakabe A, Hata N, Yamamoto M, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J. 2014 ; 78 : 911-21.
PubMed
8) Jujo K, Saito K, Ishida I, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail. 2016 ; 3 : 177-88.
PubMed
9) Komiya S, Katsumata M, Ozawa M, et al. Efficacy of tolvaptan on advanced chronic kidney disease with heart failure : a randomized controlled trial. Clin Exp Nephrol. 2022 ; 26 : 851-8.
PubMed
10) Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics : a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011 ; 25 Suppl 1 : S33-45.
 
11) Kinugawa K, Sato N, Inomata T, et al. Novel risk score efficiently prevents tolvaptan-induced hypernatremic events in patients with heart failure. Circ J. 2018 ; 82 : 1344-50.
PubMed
12) Uno T, Hosomi K, Yokoyama S, et al. Trends in tolvaptan prescription and the association between hypernatremia and aging in tolvaptan-treated patients in Japan : Real-world data mining using Japanese databases. Int J Clin Pharmacol Ther. 2023 ; 61 : 33-6.
PubMed
13) Sato N, Uno S, Kurita Y, et al. Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure. ESC Heart Fail. 2022 ; 9 : 3275-86.
PubMed
14) Kinugawa K, Nakata E, Hirano T, et al. Tolerability of the intravenously administered tolvaptan prodrug, OPC-61815, in patients with congestive heart failure who have difficulty with, or are incapable of, oral intake (TRITON-HF) -A phase III, multicenter, open-label trial. Circ J. 2022 ; 86 : 1068-78.
PubMed
15) Matsue Y, Ter Maaten JM, Suzuki M, et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clin Res Cardiol. 2017 ; 106 : 802-12.
PubMed
16) Imamura T, Kinugawa K, Minatsuki S, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J. 2013 ; 77 : 1208-13.
PubMed
17) Kakeshita K, Koike T, Imamura T, et al. Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure. Clin Exp Nephrol. 2023 ; 27 : 427-34.
PubMed
18) Takimura H, Kurozumi A, Taniguchi R, et al. Predictors of poor very early diuretic response and effectiveness of early tolvaptan in symptomatic acute heart failure. Am J Cardiovasc Drugs. 2023 ; 23 : 185-96.
PubMed
P.92 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版).
Medical*Online
2) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022 ; 24 : 4-131.
 
3) Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
4) Matsue Y, Damman K, Voors AA, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017 ; 69 : 3042-51.
PubMed
5) Greene SJ, Triana TS, Ionescu-Ittu R, et al. In-hospital therapy for heart failure with reduced ejection fraction in the United States. JACC Heart Fail. 2020 ; 8 : 943-53.
PubMed
6) Kuroda S, Damman K, Ter Maaten JM, et al. Very early diuretic response after admission for acute heart failure. J Card Fail. 2019 ; 25 : 12-9.
PubMed
7) Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017 ; 377 : 1964-75.
PubMed
8) Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022 ; 387 : 1185-95.
PubMed
9) Hanberg JS, Rao V, Ter Maaten JM, et al. Hypochloremia and diuretic resistance in heart failure : Mechanistic insights. Circ Heart Fail. 2016 ; 9 : 10.1161.
 
10) Ter Maaten JM, Damman K, Hanberg JS, et al. Hypochloremia, Diuretic resistance, and outcome in patients with acute heart failure. Circ Heart Fail. 2016 ; 9 : e003109.
PubMed
11) Costanzo MR, Guglin ME, Saltzberg MT, et al. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 ; 49 : 675-83.
PubMed
12) Bart BA, Goldsmith SR, Lee KL, et al. Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012 ; 367 : 2296-304.
PubMed
13) Verbrugge FH. Editor's Choice-Diuretic resistance in acute heart failure. Eur Heart J Acute Cardiovasc Care. 2018 ; 7 : 379-89.
 

4章 強心薬

P.104 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン 急性・慢性心不全診療ガイドライン (2017年改訂版).
Medical*Online
2) Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guideline for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016 ; 37 : 2129-200.
PubMed
3) De Backer D, et al. Coparison if dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010 ; 326 : 779-89.
 
4) Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure : a systematic review and meta-analysis of randomized controlled trials. Intensive Care Med. 2012 ; 38 ; 359-67.
PubMed
5) Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications : am analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005 ; 46 ; 57-64.
 
6) Mebazza A, et al. Short-term survival by treatment among patients hospitalized with acute heart failure : the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011 ; 37 ; 290-301.
 
7) O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure : Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999 ; 138 : 78-86.
PubMed
P.110 掲載の参考文献
1) Opie LH. Heart physiology : from cell to circulation. Philadelphia : Lippincott Williams & Wilkins ; 2004.
 
2) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版). www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf.
 
3) Cuffe MS, Califf RM, Adams KF, et al. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure : a randomized controlled trial. JAMA. 2002 ; 287 : 1541-7.
PubMed
4) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 : 3599-3726.
PubMed
5) Heidenreich PA, Bozkurt B, Auilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
6) Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications : an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005 ; 46 : 57-64.
 
7) Felker GM, Benza RL, Chandler AB, et al. OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure : results from the OPTIME-CHF study. J Am Coll Cardiol. 2003 ; 41 : 997-1003.
PubMed
8) Koster G, Bekema HJ, Wetterslev J, et al. Milrinone for cardiac dysfunction in critically ill adult patients : a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2016 ; 42 : 1322-35.
PubMed
9) Baruch L, Patacsil P, Hameed A, et al. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J. 2001 ; 141 : 266-73.
PubMed
10) Hasei M, Uchiyama A, Nishimura M, et al. Correlation between plasma milrinone concentration and renal function in patients with cardiac disease. Acta Anaesthesiol Scand. 2008 ; 52 : 991-6.
PubMed
11) Mathew R, Santo PE, Jung RG, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med. 2021 ; 385 : 516-25.
 
12) 花田裕之. 心不全の治療戦略とホスホジエステラーゼ (PDE) III 阻害薬の役割. Prog Med. 2005 ; 25 : 2808-13.
Medical*Online
13) Gilbert EM, Hershberger RE, Wiechmann RJ, et al. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995 ; 108 : 1524-32.
PubMed
14) Hirota W, Katsuya K, Nobuhisa H, et al. Acute efficacy of combined PDE III-inhibitor and low-dose dobutamine therapy in patients with acute exacerbation of chronic heart failure receiving beta-blocker. J Cardiol Jpn Ed. 2008 ; 1 : 148-54.
 
15) Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure. Circ Heart Fail. 2015 ; 8 : 880-6.
PubMed
P.116 掲載の参考文献
1) Packer M, Carver JR, Rodeheffer RJ, et al. Effect of milrinone on mortality in severe heart failure. N Eng J Med. 1991 ; 325 : 1468-75.
 
2) Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 1998 ; 339 : 1810-6.
PubMed
3) Shaker SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998 ; 31 : 1336-40.
 
4) Yoshikawa T, Baba A, Suzuki M, et al. Effectiveness of carvedilol alone versus carvedilol+pimobendan for sever congestive heart failure. Am J Cardiol. 2000 ; 85 : 1495-7.
PubMed
5) Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure : main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996 ; 76 : 223-31.
PubMed
6) The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure. Circ J. 2002 ; 66 : 149-57.
 
7) Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet. 1997 ; 349 ; 971-7.
PubMed
8) The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990 ; 336 : 1-6.
 
P.121 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン. (2017年改訂版).
Medical*Online
2) Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction : the ROSE acute heart failure randomized trial. JAMA. 2013 ; 310 : 2533-43.
 
3) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 : 3599-726.
PubMed
4) Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001 ; 345 : 588-95.
 
5) Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008 ; 358 : 877-87.
PubMed
6) Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness : the ESCAPE trial. JAMA. 2005 ; 294 : 1625-33.
PubMed
7) Sotomi Y, Sato N, Kajimoto K, et al. Impact of pulmonary artery catheter on outcome in patients with acute heart failure syndromes with hypotension or receiving inotropes : from the ATTEND Registry. Int J Cardiol. 2014 ; 172 : 165-72.
PubMed
8) Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications : an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005 ; 46 : 57-64.
 
9) De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010 ; 362 : 779-89.
 
P.126 掲載の参考文献
1) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 : 3599-726.
PubMed
2) Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002 ; 39 : 798-803.
PubMed
3) O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure : insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999 ; 138 : 78-86.
PubMed
4) Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003 ; 41 : 1797-804.
PubMed
5) Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the pulmonary artery catheter in critically ill patients : meta-analysis of randomized clinical trials. JAMA. 2005 ; 294 : 1664-70.
PubMed
6) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版).
Medical*Online
7) De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010 ; 362 : 779-89.
 
P.132 掲載の参考文献
1) Stevenson LW, Pagani FD, Young JB, et al. INTERMACS Profiles of advanced heart failure : The current picture. J Heart Lung Transplant. 2009 ; 28 : 535-41.
PubMed
2) 補助人工心臓治療関連学会協議会 インペラ部会 https://j-pvad.jp/facility/
 
3) Kondo T, Sawamura A, Okumura T, et al. Promising method for management of venoarterial extracorporeal membrane oxygenation : A case of severe heart failure successfully stabilized by "high-flow/vasodilation method". J Cardiol Cases. 2018 ; 18 : 81-4.
 

5章 血管拡張薬

P.142 掲載の参考文献
1) Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates. Am Heart J. 1985 ; 110 (1 Pt 2) : 216-24.
 
2) Mebazaa A, Gheorghiade M, Pina IL, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008 ; 36 (1 Suppl) : S129-39.
 
3) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 ; 42 : 3599-726.
 
4) Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998 ; 351 : 389-93.
PubMed
5) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版). Circulation Journal. 2018 ; http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf
 
6) Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
7) Cintron GB, Glasser SP, Weston BA, et al. Effect of intravenous isosorbide dinitrate versus nitroglycerin on elevated pulmonary arterial wedge pressure during acute myocardial infarction. Am J Cardiol. 1988 ; 61 : 21-5.
PubMed
8) Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J. 1994 ; 128 : 137-46.
PubMed
9) Danahy DT, Aronow WS. Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use. Circulation. 1977 ; 56 : 205-12.
PubMed
10) 日本循環器学会/日本心不全学会合同ガイドライン. フォーカスアップデート版 急性・慢性心不全診療ガイドライン (2021年). Circulation Journal. 2021 ; https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf
 
11) Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996 ; 335 : 1107-14.
 
12) Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee ; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991 ; 83 : 52-60.
 
13) Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation. 1996 ; 94 : 346-52.
PubMed
P.149 掲載の参考文献
1) Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998 ; 339 : 321-8.
PubMed
2) Kuroda S, Damman K, Ter Maaten JM, et al. Very early diuretic response after admission for acute heart failure. J Card Fail. 2019 ; 25 : 12-9.
PubMed
3) Hata N, Seino Y, Tsutamoto T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure : the PROTECT multicenter randomized controlled study. Circ J. 2008 ; 72 : 1787-93.
 
4) Matsue Y, Kagiyama N, Yoshida K, et al. Carperitide is associated with increased in-hospital mortality in acute heart failure : A propensity score-matched analysis. J Card Fail. 2015 ; 21 : 859-64.
PubMed
5) Nagai T, Iwakami N, Nakai M, et al. and investigators J-D. Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure : Insight from a nationwide claim-based database. Int J Cardiol. 2019 ; 280 : 104-9.
 
6) Nogi K, Ueda T, Matsue Y, et al. Effect of carperitide on the 1 year prognosis of patients with acute decompensated heart failure. ESC Heart Fail. 2022 ; 9 : 1061-70.
PubMed
7) Rush CJ, Campbell RT, Jhund PS, et al. Association is not causation : treatment effects cannot be estimated from observational data in heart failure. Eur Heart J. 2018 ; 39 : 3417-38.
 
8) Matsumoto S, Nakazawa G, Ohno Y, et al. Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction : deficiency of atrial natriuretic peptide and replacement therapy. ESC Heart Fail. 2020 ; 7 : 4172-81.
PubMed
9) O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011 ; 365 : 32-43.
PubMed
P.155 掲載の参考文献
1) Kukovetz WR, Holzmann S, Poch G. Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol. 1992 ; 20 : S1-7.
PubMed
2) Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol. 1987 ; 10 Suppl 1 : S121-31.
 
3) Brayden JE. Functional roles of KATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol. 2002 ; 29 : 312-6.
PubMed
4) Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol. 2000 ; 35 : 345-51.
 
5) Hongo M, Takenaka H, Uchikawa S, et al. Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol. 1995 ; 75 : 246-50.
PubMed
6) Niwano S, Hirasawa S, Niwano H, et al. Cardioprotective effects of sarcolemmal and mitochondrial K-ATP channel openers in an experimental model of autoimmune myocarditis. Role of the reduction in calcium overload during acute heart failure. Int Heart J. 2012 ; 53 : 139-45.
 
7) Luo B, Wu P, Bu T, et al. All-cause mortality and cardiovascular events with nicorandil in patients with IHD : systematic review and meta-analysis of the literature. Int J Cardiol. 2014 ; 176 : 661-9.
PubMed
8) IONA study group. Effect of nicorandil on coronary events in patients with stable angina : the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002 ; 359 : 1269-75.
 
9) Tanaka K, Kato K, Takano T, et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. J Cardiol. 2010 ; 56 : 291-9.
PubMed
10) Minami Y, Nagashima M, Kajimoto K, et al. Acute efficacy and safety of intravenous administration of nicorandil in patients with acute heart failure syndromes : usefulness of noninvasive echocardiographic hemodynamic evaluation. J Cardiovasc Pharmacol. 2009 ; 54 : 335-40.
PubMed
11) Ishihara S, Koga T, Kaseda S, et al. Effects of intravenous nicorandil on the mid-term prognosis of patients with acute heart failure syndrome. Circ J. 2012 ; 76 : 1169-76.
PubMed
12) Yoshihisa A, Sato Y, Watanabe S, et al. Decreased cardiac mortality with nicorandil in patients with ischemic heart failure. BMC Cardiovasc Disord. 2017 ; 17 : 141.
PubMed
13) Zhao F, Chaugai S, Chen P, et al. Effect of nicorandil in patients with heart failure : a systematic review and meta-analysis. Cardiovasc Ther. 2014 ; 32 : 283-96.
PubMed
14) Zhant Y, Cai Z, Ke X, et al. Effectiveness and safety of intravenous nicorandil application in patients with acute heart failure with low baseline blood pressure. Heart Lung Circ. 2022 ; 31 : 95-100
 
15) Tsutamoto T, Kinoshita M, Hisanaga T, et al. Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. Am J Cardiol. 1995 ; 75 : 1162-5.
PubMed
16) Watson A, Ozairi OA, Fraser A, et al. Nicorandil associated anal ulceration. Lancet. 2002 ; 360 : 546-7.
 
P.162 掲載の参考文献
1) Sato N, Kajimoto K, Keida T, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry). Circ J. 2013 ; 77 : 944-51.
PubMed
2) Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II) : A survey on hospitalized acute heart failure patients : Description of population. Eur Heart J. 2006 ; 27 : 2725-36.
 
3) Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States : Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005 ; 149 : 209-16.
 
4) Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011 ; 37 : 619-26.
PubMed
5) Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction : Implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012 ; 59 : 442-51.
PubMed
6) Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance redistribution of the venous reservoir as a cause of decompensation. Circ Hear Fail. 2011 ; 4 : 669-75.
 
7) Wang SY, Manyari DE, Scott-Douglas N, et al. Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin. Circulation. 1995 ; 91 : 1205-12.
PubMed
8) Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998 ; 351 : 389-93.
PubMed
9) Breidthardt T, Noveanu M, Potocki M, et al. Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure : A pilot study : Original article. J Intern Med. 2010 ; 267 : 322-30.
 
10) Alexander P, Alkhawam L, Curry J, et al. Lack of evidence for intravenous vasodilators in ED patients with acute heart failure : A systematic review. Am J Emerg Med. 2015 ; 33 : 133-41.
PubMed
11) Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007 ; 153 : 98-104.
PubMed
12) O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011 ; 365 : 32-43.
PubMed
13) Hata N, Seino Y, Tsutamoto T, et al. Effects of carperitide on the long-term prognosis of patients. Circ J. 2008 ; 72 : 1787-93.
 
14) Matsue Y, Kagiyama N, Yoshida K, et al. Carperitide is associated with increased in-hospital mortality in acute heart failure : A propensity score-matched analysis. J Card Fail. 2015 ; 21 : 859-64.
PubMed
15) Mizuno A, Iguchi H, Sawada Y, et al. The impact of carperitide usage on the cost of hospitalization and outcome in patients with acute heart failure : High value care vs. low value care campaign in Japan. Int J Cardiol. 2017 ; 241 : 243-8.
PubMed
16) McDonagh TA, Metra M, Adamo M, et al ; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 : 3599-726.
 
17) Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
18) Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF) : A randomised placebo-controlled trial. Lancet. 2013 ; 381 : 29-39.
PubMed
19) Packer M, O'Connor C, McMurray JJV, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017 ; 376 : 1956-64.
PubMed
20) Pang PS, Butler J, Collins SP, et al. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure : A randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). Eur Heart J. 2017 ; 38 : 2364-73.
PubMed
21) Nagai T, Honda Y, Nakano H, et al. Rationale and design of low-dose administration of carperitide for acute heart failure (LASCAR-AHF). Cardiovasc Drugs Ther. 2017 ; 31 : 551-557.
PubMed
P.165 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン 2017 [updated 2018年6月25日 ; cited 2018 12. 10]. Available from : http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf.
 
2) Pombo JF, Troy BL, Russell RO Jr. Left ventricular volumes and ejection fraction by echocardiography. Circulation. 1971 ; 43 : 480-90.
PubMed
3) Kusunose K, Shibayama K, Iwano H, et al. Reduced variability of visual left ventricular ejection fraction assessment with reference images : The Japanese Association of Young Echocardiography Fellows multicenter study. J Cardiol. 2018 ; 72 : 74-80.
PubMed
4) Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes : application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013 ; 61 : 77-84.
PubMed
5) Park JJ, Park JB, Park JH, et al. Global longitudinal strain to predict mortality in patients with acute heart failure. J Am Coll Cardiol. 2018 ; 71 : 1947-57.
PubMed
6) Zhang J, Gajjala S, Agrawal P, et al. Fully automated echocardiogram interpretation in clinical practice. Circulation. 2018 ; 138 : 1623-35.
PubMed
7) Ouyang D, He B, Ghorbani A, Video-based AI for beat-to-beat assessment of cardiac function. Nature. 2020 ; 580 : 252-6.
PubMed
8) He B, Kwan AC, Cho JH, et al. Blinded, randomized trial of sonographer versus AI cardiac function assessment. Nature. 2023 ; 616 : 520-4.
PubMed
P.167 掲載の参考文献
1) 2023年JCS/JSCVS/JCC/CVITガイドラインフォーカスアップデート版 PCPS/ECMO/循環補助用心内留置型ポンプカテーテルの適応・操作.
 
2) Basir MB, Schreiber TL, Grines CL, et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol. 2017 ; 119 : 845-51.
PubMed
3) Kapur NK, Kim RJ, Moses JW, et al. Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction : Rationale and design of the STEMI-DTU randomized pivotal trial. Am Heart J. 2022 ; 254 : 122-32.
PubMed

6章 抗不整脈薬

P.173 掲載の参考文献
1) Vassallo P, Trohman RG. Prescribing amiodarone. JAMA. 2007 ; 298 : 1312.
PubMed
2) Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007 ; 356 : 935-41.
PubMed
3) Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000 ; 342 : 913-20.
 
4) Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation : a systematic review of randomized controlled trials. Arch Intern Med. 2006 ; 166 : 719-28.
PubMed
5) Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators : the OPTIC Study : a randomized trial. JAMA. 2006 ; 295 : 165-71.
PubMed
6) 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf.
 
7) Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 ; 352 : 2146.
 
8) Fishbein DP, Hellkamp AS, Mark DB, et al. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol. 2014 ; 63 : 2560-8.
 
9) Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001 ; 29 : 1149-53.
PubMed
10) Hofmann R, Steinwender C, Kammler J, et al. Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. Int J Cardiol. 2006 ; 110 : 27-32.
 
11) Epstein AE, Olshansky B, Naccarelli GV, et al. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2016 ; 129 : 468-75.
PubMed
12) Schwaiblmair M, Berghaus T, Haeckel T, et al. Amiodarone-induced pulmonary toxicity : An under-recognized and severe adverse effect? Clin Res Cardiol. 2010 ; 99 : 693-700.
PubMed
13) Razvi S, Jabbar A, Pingitore A, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol. 2018 ; 71 : 1781-96.
PubMed
14) Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism : aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 2023 ; 11 : 282-98.
PubMed
15) Kaufman ES, Zimmermann PA, Wang T, et al. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study : a multivariate analysis. J Am Coll Cardiol. 2004 ; 44 : 1276-82.
PubMed
16) Kodama I, Kamiya K, Toyama J. Amiodarone : ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol. 1999 ; 84 : 20R-28R.
PubMed
17) Yasuda H, Rickard CM, Marsh N, et al. Risk factors for peripheral intravascular catheter-related phlebitis in critically ill patients : analysis of 3429 catheters from 23 Japanese intensive care units. Ann Intensive Care. 2022 ; 12 : 33.
PubMed
18) Waldo AL, Camm AJ, DeRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet (London, England). 1996 ; 348 : 7-12.
 
19) Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 ; 138 : e272-e391.
 
20) Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999 ; 341 : 857-65.
 
21) Kober L, Torp-Pedersen C, Mcmurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008 ; 358 : 2678-87.
PubMed
22) Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018 ; 378 : 417-27.
PubMed
23) Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device : Results from the AATAC multicenter randomized trial. Circulation. 2016 ; 133 : 1637-44.
 
P.181 掲載の参考文献
1) Huizar JF, Ellenbogen KA, Tan AY, et al. Arrhythmia-induced cardiomyopathy : JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 ; 73 : 2328-44.
PubMed
2) Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) : The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 ; 42 : 373-498.
 
3) Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 ; 347 : 1825-33.
PubMed
4) Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008 ; 358 : 2667-77.
PubMed
5) Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018 ; 378 : 417-27.
PubMed
6) Sohns C, Fox H, Marrouche NF, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med. 2023 ; Online ahead of print.
 
7) Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation : The CABANA Randomized Clinical Trial. JAMA. 2019 ; 321 : 1261-74.
 
8) Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020 ; 383 : 1305-16.
PubMed
9) Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 ; 37 : 2893-962.
PubMed
10) Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure : Results from the CABANA Trial. Circulation. 2021 ; 143 : 1377-90.
PubMed
11) 日本循環器学会/日本不整脈心電学会合同ガイドライン. 2020年改訂版不整脈薬物治療ガイドライン.
 
12) 日本循環器学会/日本心不全学会合同ガイドライン. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療.
 
13) Gorenek B, Halvorsen S, Kudaiberdieva G, et al. Atrial fibrillation in acute heart failure : A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care. 2020 ; 9 : 348-57.
 
14) January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society [published correction appears in Circulation. 2014 Dec 2 ; 130 (23) : e270-1]. Circulation. 2014 ; 130 : 2071-104.
 
15) Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction : comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013 ; 77 : 908-16.
 
16) Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020 ; 36 : 1847-948.
 
17) Meyer M, Lustgarten D. Beta-blockers in atrial fibrillation-trying to make sense of unsettling results. Europace. 2023 ; 25 : 260-2.
PubMed
18) Kotecha D, Bunting KV, Gill SK, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life : The RATE-AF Randomized Clinical Trial. JAMA. 2020 ; 324 : 2497-508.
PubMed
19) Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J. 1990 ; 63 : 157-61.
PubMed
20) Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010 ; 362 : 1363-73.
PubMed
21) Brignole M, Pentimalli F, Palmisano P, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS : the APAF-CRT mortality trial. Eur Heart J. 2021 ; 42 : 4731-9.
PubMed
P.185 掲載の参考文献
1) Yaku H, Kaneda K, Kitamura J, et al. Kampo medicine for the holistic approach to older adults with heart failure. J Cardiol. 2022 ; 80 : 306-12.
PubMed
2) 土倉潤一郎, 高橋佑一朗, 前田ひろみ, 他. 再発性こむら返りに疎経活血湯を使用した33例の検討. 日本東洋医学雑誌. 2017 ; 68 : 40-6.
 
3) Imamura T, Hori M, Tanaka S, et al. Successful management of refractory constipation using Kampo medicine Mashiningan in a patient with wild-type ATTR cardiac amyloidosis. J Cardiol Cases. 2022 ; 25 : 34-6.
 
4) Sakisaka N, Mitani K, Sempuku S, et al. A clinical study of ninjin'yoeito with regard to frailty. Front Nutr. 2018 ; 5 : 73.
PubMed
5) Takeda H, Sadakane C, Hattori T, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology. 2008 ; 134 : 2004-13.
PubMed
6) Ohnishi N, Nagasawa K, Yokoyama T. The verification of regulatory effects of Kampo formulations on body fluid using model mice. J Traditional Med. 2000 ; 17 : 131-6.
 
7) 玉野雅裕, 豊田茂, 加藤士郎, 他. トリバプタンノンレスポンダー心不全患者における五苓散併用効果の臨床的検討. Prog Med. 2017 ; 37 : 141-6.
 
8) 川原隆, 千葉浩, 高橋浩, 他. 慢性腎臓病合併慢性心不全患者における五苓散の有用性と安全性の臨床的検討. 日本東洋医学雑誌. 2019 ; 70 : 57-64.
 
9) Yaku H, Kato T, Morimoto T, et al. Rationale and study design of the GOREISAN for Heart Failure (GOREISAN-HF) trial : A randomized clinical trial. Am Heart J. 2023 ; 260 : 18-25.
 
P.189 掲載の参考文献
1) McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 ; 381 : 1995-2008.
PubMed
2) Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020 ; 383 : 1413-24.
PubMed
3) Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e1033.
 
4) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 : 3599-726.
PubMed
5) Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. Published online 2022 : 1089-98.
 
6) Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 ; 385 : 1451-61.
PubMed
7) Cohen LP, Isaza N, Hernandez I, et al. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction. JAMA Cardiol. 2023 ; 16 : E010283.
 
8) Zheng J, Parizo JT, Spertus JA, et al. Cost-effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction. JAMA Intern Med. 2022 ; 182 : 1278-88.
PubMed
9) Zhou J, Liew D, Kaye DM, et al. Cost-effectiveness of empagliflozin in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Qual Outcomes. 2022 ; 15 : E008638.
PubMed
10) Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure : a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 ; 400 : 757-67.
PubMed
11) McEwan P, Darlington O, McMurray JJV, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction : a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail. 2020 ; 22 : 2147-56.
PubMed
12) Isaza N, Calvachi P, Raber I, et al. Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction. JAMA Netw Open. 2021 ; 4 : 1-14.
PubMed
13) Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021 ; 6 : 926-35.
PubMed

7章 心不全に併発した心房細動に対する抗凝固薬

P.213 掲載の参考文献
1) Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation. Stroke. 2006 ; 37 : 447-51.
PubMed
2) Hart RG, Pearce LA, Aguilar MI. Meta-analysis : antithrombotic therapy to prevent stroke in patiets who have non valvular atrial fibrillation. Ann Intern Med. 2007 ; 146 : 857-67.
 
3) 日本循環器学会・日本不整脈心電学会. 不整脈薬物治療ガイドライン (2018年改訂版).
 
4) Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 ; 369 : 1206-14.
PubMed
5) Connolly SJ, Karthikeyan G, Ntsekhe M, et al ; INVICTUS Investigators. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022 ; 387 : 978-88.
PubMed
6) Yamashita T, Inoue H, Okumura K, et al. Warfarin anticoagulation intensity in Japanese non valvular atrial fibrillation patients : a J-RHYTHM registry analysis. J Cardiol. 2015 ; 65 : 175-7.
 
7) Connollt SJ, Ezekowitz MD, Yusut S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 : 1139-51.
 
8) Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 : 883-91.
PubMed
9) Grander CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 ; 365 : 981-92.
 
10) Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 ; 369 : 2093-104.
PubMed
11) Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study-. Circ J. 2012 ; 76 : 2104-11.
 
12) 小田倉弘典. もう怖くない! 心房細動の抗凝固療法. 東京 : 文光堂 ; 2017. p.97-113, 139-54.
 
13) Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomized trials. Lancet. 2014 ; 383 : 955-62.
PubMed
14) Savarese G, Giugliano RP, Rosano GM, et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure : a meta-analysis. JACC Heart Fail. 2016 ; 4 : 870-80.
PubMed
15) 日本循環器学会・日本心不全学会. ガイドラインフォーカスアップデート版・心不全診療 (2021年改訂版).
 
16) Toyoda K, Yasaka M, Iwabe K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke. 2008 ; 39 : 1740-5.
 
17) Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation : the HAS-BLED score. J Am Coll Cardiol. 2011 ; 57 : 173-80.
 
18) D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene in associated with interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005 ; 105 : 645-9.
 
19) Garcia D, Regan S, Crowther M, et al. Warfarin maintenance dosing patterns in clinical practice : implication for safer anticoagulation in the elderly population. Chest. 2005 ; 127 : 2049-56.
PubMed
20) Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010 ; 56 : 823-31.
PubMed
21) Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, et al. Assessing evidence of interaction between smoking and warfarin : a systematic review and meta-analysis. Chest. 2011 ; 139 : 1130-9.
PubMed
22) Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation : observing outcomes associated with varying levels of INR control. Thromb Res. 2009 ; 124 : 37-41.
PubMed
23) Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratio : a randomized trial. Ann Intern Med. 2011 ; 155 : 653-9.
PubMed
24) Camm AJ, Cools F, Virdone S, et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol 2020 ; 76 : 1425-36.
PubMed
25) Yamashita Y, Uozumi R, Hamatani Y, et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients-Fushimi AF Registry. Circ J. 2017 ; 81 : 1278-85.
PubMed
26) Akao M, Shimizu W, Atarashi H, et al. Oral anticoagulant use in elderly Japanese patients with non-valvular atrial fibrillation -subanalysis of the ANAFIE Registry. Circ Rep 2020 ; 2 : 552-9.
PubMed
27) Chao TF, Liu CJ, Lin YJ, et al. Oral anticoagulation in very elderly patients with atrial fibrillation : a nationwide cohort study. Circulation. 2018 ; 138 : 37-47.
PubMed
28) Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018 ; 320 : 2221-30.
PubMed
29) Goto K, Nakai K, Shizuta S, et al. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol. 2014 ; 114 : 70-8.
PubMed
30) Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016 ; 375 : 2423-34.
PubMed
31) Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017 ; 377 : 1513-24.
PubMed
32) Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019 ; 380 : 1510-24.
PubMed
33) Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI) : a randomized, open-label, phase 3b trial. Lancet. 2019 ; 394 : 1335-43.
PubMed
34) Yasuda S, Kakita K, Ogawa H, et al. Antithrombotic therapy for atrial fibrillation and stable coronary disease. N Engl J Med. 2019 ; 381 : 1103-13.
 
35) Garcia DA, Crowther MA. Reversal of warfarin case-based practice recommendation. Circulation. 2012 ; 125 : 2944-7.
PubMed
36) 日本循環器学会. 非心臓手術における合併心疾患の評価と管理に関するガイドライン (2022).
 
37) Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin : the SAMe-TT2R2 score. Chest. 2013 ; 144 : 1555-63.
PubMed
38) Joosten LPT, Doorn S, van de Ven PM, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation : Results of the FRAIL-AF Randomized Controlled Trial. Circulation 2023 ; Online published.
 
39) Ikeda T, Oagawa S, Kitazono T, et al. Real-world outcomes of the Xarelto post-authorization safety & effectiveness study in Japanese patients with atrial fibrillation (XAPASS). J Cardiol. 2019 ; 74 : 60-6.
 
40) Shimokawa H, Yamashita T, Uchiyama S, et al. The EXPAND study : Efficacy and safety rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Int J Cardio. 2018 ; 258 : 126-32.
 
41) Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016 ; 150 : 1302-12.
PubMed
42) Okumura K, Yamashita T, Suzuki S, et al. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial patients (J-ELD AF Registry). Clin Cardiol. 2020 ; 43 ; 251-9.
 
43) Lee SR, Choi EK, Han KD, et al. Edoxaban in Asian patients with atrial fibrillation : Effectiveness and safety. J Am Coll Cardiol. 2018 ; 72 : 838-53.
PubMed
44) Okumura K, Akao M, Yoshida T, et, al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020 ; 383 : 1735-45.
 
45) Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation : implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011 : 57 : 1339-48.
 
46) Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012 ; 367 : 625-35.
PubMed
47) 日本透析医学会. 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 日透析医学会誌. 2011 ; 44 : 337-425.
 
48) January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019 ; 140 : e125-51.
PubMed
49) Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guideline for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020 ; 42 : 373-498.
 
50) Pokorney SD, Chertow GM, AI-Khalidi H, et al. Apixaban for patients with atrial fibrillation on hemodialysis : a multicenter randomized controlled trial. Circulation. 2020 ; 23 : 1735-45.
 
51) Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart failure (WASH) : A randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004 ; 148 : 157-64.
 
52) Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure : the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009 ; 119 : 1616-24.
PubMed
53) Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012 ; 366 : 1859-69.
PubMed
54) Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018 ; 379 : 1332-42.
PubMed
55) Kondo T, Abdul-Rahim AH, Talebi A, et al. Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. Eur Heart J. 2022 ; 43 : 4469-79.
PubMed
56) Levine GN, McEvoy JW, Fang JC, et al. Management of patients at risk for and with left ventricular thrombus : a scientific statement from the American Heart Association. Circulation. 2022 ; 146 : e205-23.
PubMed
P.220 掲載の参考文献
1) Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy : Executive summary : A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020 ; 76 : 3022-55.
 
2) Terasaka N, Spanopoulos D, Miyagoshi H, et al. Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan : A nationwide medical claims database study. J Cardiol. 2023 ; 81 : 316-22.
PubMed
3) Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021 ; 78 : 2505-17.
PubMed
4) Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 ; 396 : 759-69.
PubMed
5) Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022 ; 80 : 95-108.
PubMed
6) Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023 ; 81 : 34-45.
PubMed
7) Kitaoka H, Tsutsui H, Kubo T, et al. JCS/JHFS 2018 Guideline on the diagnosis and treatment of cardiomyopathies. Circ J. 2021 ; 85 : 1590-689.
PubMed
8) Rowin EJ, Hausvater A, Link MS, et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2017 ; 136 : 2420-36.
PubMed
9) Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001 ; 104 : 2517-24.
PubMed
10) Providencia R, Elliott P, Patel K, et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy : a systematic review and meta-analysis. Heart. 2016 ; 102 : 1533-43.
PubMed
P.223 掲載の参考文献
1) Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015 ; 36 : 2585-94.
PubMed
2) 日本循環器学会2020年版 心アミロイドーシス診療ガイドライン https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2020_Kitaoka.pdf 2023年3月閲覧
 
3) Inomata T, Tahara N, Nakamura K, et al. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan : red-flag symptom clusters and diagnostic algorithm. ESC Heart Fail. 2021 ; 8 : 2647-59.
PubMed
4) Sperry BW, Hanna M, Shah SJ, et al. Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis : Results from TOPCAT. JACC Heart Fail. 2021 ; 9 : 795-802.
PubMed
5) Ternacle J, Krapf L, Mohty D, et al. Aortic stenosis and cardiac amyloidosis : JACC Review Topic of the Week. J Am Coll Cardiol. 2019 ; 74 : 2638-51.
 
6) Maurer MS, Schwartz JH, Gundapaneni B, et al ; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018 ; 379 : 1007-16.
 
7) Kastritis E, Palladini G, Minnema MC, et al ; ANDROMEDA Trial Investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021 ; 385 : 46-58.
PubMed

8章 その他の薬剤

P.228 掲載の参考文献
1) Gheorghiade M, Pitt B. Digitalis Investigation Group (DIG) trial. a stimulus for further research. Am Heart J. 1997 ; 134 : 3-12.
 
2) Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010 ; 21 : 1550-9.
PubMed
3) Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation : findings from the TREAT-AF study. J Am Coll Cardiol. 2014 ; 64 : 660-8.
PubMed
4) Shah M, Avgil Tsadok M, Jackevicius CA, et al. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ?65 years of age with versus without heart failure. Am J Cardiol. 2014 ; 114 : 401-6.
PubMed
5) Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin : systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015 ; 351 : h4451.
PubMed
6) Hindricks G, Potapara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2021 ; 42 : 373-498.
 
7) Vamos M, Erath JW, Benz AP, et al. Meta-analysis of effects of digoxin on survival in patients with atrial fibrillation or heart failure : An update. Am J Cardiol. 2019 ; 123 : 69-74.
PubMed
8) Wang X, Luo Y, Xu D, et al. Effect of digoxin therapy on mortality in patients with atrial fibrillation : An updated meta-analysis. Front Cardiovasc Med. 2021 ; 8 : 731135.
 
9) Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis. Lancet. 2014 ; 384 : 2235-43.
PubMed
10) Kotecha D, Bunting KV, Gill SK, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life : The RATE-AF Randomized Clinical Trial. JAMA. 2020 ; 324 : 2497-508.
PubMed
P.232 掲載の参考文献
1) Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007 ; 50 : 823-30.
PubMed
2) Mulieri LA, Hasenfuss G, Leavitt B, et al. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992 ; 85 : 1743-50.
PubMed
3) Castagno D, Skali H, Takeuchi M, et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure : results from the CHARM (Candesartan in Heart Failure : Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol. 2012 ; 59 : 1785-95.
 
4) Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 2002 ; 34 : 951-69.
PubMed
5) Cullington D, Goode KM, Zhang J, et al. Is heart rate important for patients with heart failure in atrial fibrillation? JACC Heart Fail. 2014 ; 2 : 213-20.
PubMed
6) Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL) : a subgroup analysis of a randomised controlled trial. Lancet. 2008 ; 372 : 817-21.
PubMed
7) Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008 ; 101 : 865-9.
PubMed
8) McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis : beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009 ; 150 : 784-94.
PubMed
9) Porapakkham P, Porapakkham P, Krum H. Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure? Cardiovasc Ther. 2010 ; 28 : 93-100.
PubMed
10) Fiuzat M, Wojdyla D, Pina I, et al. Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction : Results from the HF-ACTION Trial. JACC Heart Fail. 2016 ; 4 : 109-15.
 
11) Bhatt AS, DeVore AD, DeWald TA, et al. Achieving a maximally tolerated beta-blocker dose in heart failure patients : Is there room for improvement? J Am Coll Cardiol. 2017 ; 69 : 2542-50.
PubMed
12) Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL) : a randomised, double-blind, placebo-controlled trial. Lancet. 2008 ; 372 : 807-16.
PubMed
13) Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebo-controlled study. Lancet. 2010 ; 376 : 875-85.
PubMed
14) Tardif JC, O'Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function : results from the SHIFT echocardiography substudy. Eur Heart J. 2011 ; 32 : 2507-15.
PubMed
15) Borer JS, Bohm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure : the SHIFT Study. Eur Heart J. 2012 ; 33 : 2813-20.
PubMed
16) Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction : a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013 ; 34 : 2263-70.
PubMed
17) 2021年JCS/JHFS ガイドライン フォーカスアップデート版. 急性・慢性心不全診療.
Medical*Online
18) Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure : is there an influence of beta-blocker dose? : findings from the SHIFT (Systolic Heart failure treatment with the I (f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012 ; 59 : 1938-45.
 
19) Bagriy AE, Schukina EV, Samoilova OV, et al. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Adv Ther. 2015 ; 32 : 108-19.
 
20) Dominjon F, Henon-Goburdhun C, Pannaux M, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction : the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017 ; 19 : 1495-503.
 
P.240 掲載の参考文献
1) Gallo G, Rubattu S, Volpe M. Targeting cyclic guanylate monophosphate in resistant hypertension and heart failure : Are sacubitril/valsartan and vericiguat synergistic and effective in both conditions? High Blood Press Cardiovasc Prev. 2021 ; 28 : 541-5.
PubMed
2) Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020 ; 382 : 1883-93.
PubMed
3) Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem. 2017 ; 60 : 5146-61.
PubMed
4) Ezekowitz JA, O'Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes : Vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 2020 ; 8 : 931-9.
 
5) Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction : The VITALITY-HFpEF randomized clinical trial. JAMA. 2020 ; 324 : 1512-21.
PubMed
6) Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2022 ; 10 : 73-84.
PubMed
7) 筒井裕之. 日本循環器学会/日本心不全学会合同ガイドライン. JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療. 2021.
 
8) Task Force M, McDonagh TA, Metra M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022 ; 24 : 4-131.
 
9) Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ; 145 : e895-e1032.
 
10) Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction : a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013 ; 128 : 502-11.
PubMed
11) Butler J, Usman MS, Anstrom KJ, et al. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. Eur J Heart Fail. 2022 ; 24 : 2029-36.
PubMed
12) Liang WL, Liang B. Soluble guanylate cyclase activators and stimulators in patients with heart failure. Curr Cardiol Rep. 2023 ; 25 : 607-13.
PubMed
P.246 掲載の参考文献
1) Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med. 1991 ; 325 : 1468-75.
 
2) O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure : insights from the flolan international randomized survival trial (FIRST). Am Heart J. 1999 ; 138 (1 Pt 1) : 78-86.
 
3) Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure : a randomized controlled trial. JAMA. 2002 ; 287 : 1541-7.
PubMed
4) Morgan BP, Muci A, Lu PP, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. ACS Med Chem Lett. 2010 ; 1 : 472-7.
PubMed
5) Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation : a potential therapeutic approach for systolic heart failure. Science. 2011 ; 331 : 1439-43.
PubMed
6) Malik FI, Morgan BP. Cardiac myosin activation part 1 : from concept to clinic. J Mol Cell Cardiol. 2011 ; 51 : 454-61.
PubMed
7) Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil : a first-in-man study. Lancet. 2011 ; 378 : 667-75.
PubMed
8) Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure : a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 ; 378 : 676-83.
PubMed
9) Greenberg BH, Chou W, Saikali KG, et al. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015 ; 3 : 22-9.
PubMed
10) Lewis GD, Voors AA, Cohen-Solal A, et al. Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction : The METEORIC-HF Randomized Clinical Trial. JAMA. 2022 ; 328 : 259-69.
PubMed
11) Nanasi P Jr, Gaburjakova M, Gaburjakova J, et al. Omecamtiv mecarbil activates ryanodine receptors from canine cardiac but not skeletal muscle. Eur J Pharmacol. 2017 ; 809 : 73-9.
 
12) Liu LC, Dorhout B, van der Meer P, et al. Omecamtiv mecarbil : a new cardiac myosin activator for the treatment of heart failure. Expert Opin Investig Drugs. 2016 ; 25 : 117-27.
PubMed
13) Teerlink JR, Diaz R, Felker GM, et al. GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021 ; 384 : 105-16.
PubMed
14) Cytokinetics社 ホームページ. https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-receives-complete-response-letter-fda-new-drug
 
P.251 掲載の参考文献
1) Pieroni M, Moon JC, Arbustini E, et al. Cardiac involvement in Fabry disease : JACC Review Topic of the Week. J Am Coll Cardiol. 2021 ; 77 : 922-36.
 
2) Nordin S, Kozor R, Medina-Menacho K, et al. Proposed stages of myocardial phenotype development in Fabry disease. JACC Cardiovasc Imaging. 2019 ; 12 : 1673-83.
PubMed
3) Kobayashi M, Ohashi T, Sakuma M, et al. Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis. 2008 ; 31 Suppl 3 : 483-7.
 
4) Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease : cardiac outcomes after 10 years' treatment. Orphanet J Rare Dis. 2015 ; 10 : 125.
PubMed
5) Beck M, Hughes D, Kampmann C, et al. Fabry Outcome Survey Study Group. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease : A Fabry Outcome Survey analysis. Mol Genet Metab Rep. 2015 ; 3 : 21-7.
 

9章 PV loop から考える薬の考え方, 使い方

P.265 掲載の参考文献
1) Frank O. Die Grundform des arteriellen pulses. Z Biol. 1899 ; 37 : 483-526.
 
2) Sagawa K, Maughan L, Suga H, et al. Cardiac contraction and the pressure-volume relationship. Oxford University Press ; 1988.
 
3) Suga H. Ventricular energetics. Physiol Rev. 1990 ; 70 : 247-77.
 
4) Sakamoto T, Kakino T, Sakamoto K, et al. Changes in vascular properties, not ventricular properties, predominantly contribute to baroreflex regulation of arterial pressure. Am J Physiol Heart Circ Physiol. 2015 ; 308 : H49-58.
 
5) Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Eng J Med. 2004 ; 350 : 1953-9.
 
6) Guyton AC. Determination of cardiac output by equating venous return curves with cardiac response curves. Physiol Rev. 1955 ; 35 : 123-9.
PubMed

10章 心不全に合併する電解質異常の治療

P.272 掲載の参考文献
1) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 : 3599-726.
PubMed
2) Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the Management of Heart Failure. J Card Fail. 2022 ; 28 : 810-30.
PubMed
3) Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010 ; 3 : 25-32.
 
4) Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model : prediction of survival in heart failure. Circulation. 2006 ; 113 : 1424-33.
PubMed
5) Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999 ; 341 : 577-85.
PubMed
6) Dunlap ME, Hauptman PJ, Amin AN et al. Current management of hyponatremia in acute heart failure : a report from the hyponatremia registry for patients with euvolemic and hypervolemic hyponatremia (HN Registry). J Am Heart Assoc. 2017 ; 6 : e005261.
PubMed
7) Covic A, Copur S, Tapoi L, et al. Efficiency of hypertonic saline in the management of decompensated heart failure : A systematic review and meta-analysis of clinical studies. Am J Cardiovasc Drugs. 2021 ; 21 : 331-47.
PubMed
8) Konstam MA, Gheorghiade M, Burnett JC Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA. 2007 ; 297 : 1319-31.
PubMed
9) Dzau VJ, Hollenberg NK. Renal response to captopril in severe heart failure : role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med. 1984 ; 100 : 777-82.
PubMed
10) Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure : an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007 ; 28 : 980-8.
PubMed
11) Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of potassium in heart failure : JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 ; 75 : 2836-50.
PubMed
12) Krogager ML, Kragholm K, Thomassen JQ, et al. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease : a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother. 2021 ; 7 : 557-67.
 
13) Rossignol P, Dobre D, McMurray JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy : results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 ; 7 : 51-8.
PubMed
14) Maggioni AP, Anker SD, Dahlstrom U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013 ; 15 : 1173-84.
 
15) Rossignol P, Lainscak M, Crespo-Leiro MG, et al. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020 ; 22 : 1378-89.
PubMed
16) Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015 ; 372 : 222-31.
PubMed
17) Bridgeman MB, Shah M, Foote E. Potassium-lowering agents for the treatment of nonemergent hyperkalemia : pharmacology, dosing and comparative efficacy. Nephrol Dial Transplant. 2019 ; 34 (Suppl 3) : iii45-50.
 
18) Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction : the DIAMOND trial. Eur Heart J. 2022 ; 43 : 4362-73.
PubMed
19) Desai AS, Vardeny O, Claggett B, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril : A secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 ; 2 : 79-85.
PubMed
20) Ferreira JP, Zannad F, Butler J, et al. Empagliflozin and serum potassium in heart failure : an analysis from EMPEROR-Pooled. Eur Heart J. 2022 ; 43 : 2984-93.
PubMed

11章 心不全に合併する貧血の治療

P.279 掲載の参考文献
1) Kajimoto K, Sato N, Sakata Y, et al. Relationship between systolic blood pressure and preserved or reduced ejection fraction at admission in patients hospitalized for acute heart failure syndromes. Int J Cardiol. 2013 ; 168 : 4790-5.
PubMed
2) Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa K, et al. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan. Circ J. 2009 ; 73 : 1901-8.
 
3) Naito Y, Tsujino T, Fujimori Y, et al. Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J Hypertens. 2011 ; 29 : 741-8.
PubMed
4) Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006 ; 48 : 2485-9.
PubMed
5) Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency : an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010 ; 31 : 1872-80.
PubMed
6) Gregory D, Rajeev M, Adrian F, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency. The IRONOUT HF Randomized Clinical Trial. JAMA. 2017 ; 317 : 1958-66.
 
7) Stefan D, Josep C, Gerasimos F, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009 ; 361 : 2436-48.
 
8) Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure : a multicentre, double-blind, randomised, controlled trial. Lancet. 2020 ; 396 : 1895-904.
PubMed
9) Guidelines for diagnosis and treatment of acute and chronic heart failure (JCS 2017/JHFS 2017).
 
10) Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002 ; 4 : 681-6.
PubMed
11) Swedberg K, Young JB, Anand IS, et al. RED-HF Committees ; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013 ; 368 : 1210-9.
PubMed
12) 内田啓子, 南学正臣, 阿部雅紀, 他. 日本腎臓学会. HIF-PH阻害薬適正使用に関するrecommendation. 日腎会誌. 2020 ; 62 : 711-6.
 
13) Yap DYH, McMahon LP, Hao CM, et al. Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology (Carlton). 2021 ; 26 : 105-18.
PubMed

12章 心不全に合併する高尿酸血症の治療

P.284 掲載の参考文献
1) Ichida K, Matsuo H, Takada T, et al. Decreased extra?renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012 ; 3 : 764.
PubMed
2) FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020 ; 72 : 744-60.
PubMed
3) Hisatome I, Li P, Miake J, et al. Uric acid as a risk factor for chronic kidney disease and cardiovascular disease-Japanese guideline on the management of asymptomatic hyperuricemia. Circ J. 2021 ; 85 : 130-8.
PubMed
4) Miao L, Guo M, Pan D, et al. Serum uric acid and risk of chronic heart failure : A systematic review and meta-analysis. Front Med (Lausanne). 2021 ; 8 : 785327.
PubMed
5) Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, et al. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol. 2011 ; 151 : 143-7.
PubMed
6) Kobayashi Y, Omote K, Nagai T, et al. Prognostic value of serum uric acid in hospitalized heart failure patients with preserved ejection fraction (from the Japanese Nationwide Multicenter Registry). Am J Cardiol. 2020 ; 125 : 772-6.
PubMed
7) Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients : The xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015 ; 131 : 1763-71.
 
8) Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020 ; 382 : 2504-13.
PubMed
9) Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020 ; 382 : 2493-503.
PubMed
10) Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART) : a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022 ; 400 : 1195-205.
 
11) Saito Y, Tanaka A, Node K, et al. Uric acid and cardiovascular disease : A clinical review. J Cardiol. 2021 ; 78 : 51-7.
PubMed
12) White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018 ; 378 : 1200-10.
 
13) Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST) : a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020 ; 396 : 1745-57.
 
14) Doehner W, Anker SD, Butler J, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction : the EMPEROR-reduced trial. Eur Heart J. 2022 ; 43 : 3435-46.
PubMed

13章 アドヒアランスを意識した薬剤使用とポリファーマシー

P.290 掲載の参考文献
1) Tsuchihashi M, Tsutsui H, Kodama K, et al. Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure. Am Heart J. 2001 ; 142 : E7.
PubMed
2) Wu J-R, Moser DK. Medication adherence mediates the relationship between heart failure symptoms and cardiac event-free survival in patients with heart failure. J Cardiovasc Nurs. 2018 ; 33 : 40-6.
PubMed
3) Fumagalli LP, Radaelli G, Lettieri E, et al. Patient empowerment and its neighbours : clarifying the boundaries and their mutual relationships. Health Policy. 2015 ; 119 : 384-94.
PubMed
4) Hood SR, Giazzon AJ, Seamon G, et al. Association between medication adherence and the outcomes of heart failure. Pharmacotherapy. 2018 ; 38 : 539-45.
PubMed
5) Ruppar TM, Cooper PS, Mehr DR, et al. Medication adherence interventions improve heart failure mortality and readmission rates : Systematic review and meta-analysis of controlled trials. J Am Heart Assoc. 2016 ; 5 (6). pii : e002606.
 
6) Wu JR, Moser DK, De Jong MJ, et al. Defining an evidence-based cutpoint for medication adherence in heart failure. Am Heart J. 2009 ; 157 : 285-91.
PubMed
7) Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986 ; 24 : 67-74.
PubMed
8) Dolansky MA, Hawkins MA, Schaefer JT, et al. Association between poorer cognitive function and reduced objectively monitored medication adherence in patients with heart failure. Circ Heart Fail. 2016 ; 9 : e002475.
PubMed
9) Riegel B, Dickson VV. A qualitative secondary data analysis of intentional and unintentional medication nonadherence in adults with chronic heart failure. Heart Lung. 2016 ; 45 : 468-74.
PubMed
10) Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 ; 353 : 487-97.
PubMed
11) Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease : meta-analysis on 376,162 patients. Am J Med. 2012 ; 125 : 882-7. e1.
 
12) Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012 ; 28 : 669-80.
PubMed
13) Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001 ; 23 : 1296-310.
 
14) Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance : a meta-analysis. Am J Med. 2007 ; 120 : 713-9.
PubMed
15) Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD : the UMPIRE randomized clinical trial. JAMA. 2013 ; 310 : 918-29.
PubMed
16) Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007 ; 64 : 1279-83.
PubMed
17) Liu F, Ghaffur A, Bains J, et al. Acceptability of oral solid medicines in older adults with and without dysphagia : A nested pilot validation questionnaire based observational study. Int J Pharm. 2016 ; 512 : 374-81.
PubMed
18) Gray R, Indraratna P, Lovell N, et al. Digital health technology in the prevention of heart failure and coronary artery disease. Cardiovasc Digit Health J. 2022 ; 3 (6 Suppl) : S9-16.
 
19) Farwati M, Riaz H, Tang WHW. Digital health applications in heart failure : a critical appraisal of literature. Curr Treat Options Cardiovasc Med. 2021 ; 23 : 12.
PubMed
P.294 掲載の参考文献
1) Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan : rationale and design of Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2006 ; 70 : 1617-23.
 
2) Banerjee A, Mbamalu D, Ebrahimi S, et al. The prevalence of polypharmacy in elderly attenders to an emergency department-a problem with a need for an effective solution. Int J Emerg Med. 2011 ; 4 : 22.
 
3) Nobili A, Licata G, Salemo F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011 ; 67 : 507-19.
 
4) Kojima T, Akishita M, Kameyama Y, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs : analysis of inpatient database. Geritar Gerontol Int. 2012 ; 12 : 761-2.
PubMed
5) Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011 ; 365 : 2002-12.
PubMed
6) Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. 2020 ; 13 : e006977
PubMed
7) 厚生労働省. 診療報酬の算定方法の一部を改正する件. 令和2年告示 第57号 第2章 医学管理.
 
8) Scott IA, Hilmer SN, Martin JH, et al. Reducing inappropriate polypharmacy : the process of deprescribing. JAMA Intern Med. 2015 ; 175 : 827-34.
PubMed
9) Lee SJ, Kim CM. Individualizing prevention for older adults. J Am Geriatr Soc. 2018 ; 66, 229-34.
PubMed
10) Hill-Taylor B, Walsh KA, Stewart S, et al. Effectiveness of the STOPP/START criteria : systematic review and meta-analysis of randomized controlled studies. J Clin Pharm There. 2016 ; 41 : 158-69.
 
11) Aldred DP, Kennedy MC, Hughes C, et al. Interventions to optimize prescribing for older people in care homes. Cochrane Database Syst Rev. 2016 ; 2 : CD009095.
 

14章 麻薬, 鎮静薬の考え方, 使い方と心不全緩和ケア

P.302 掲載の参考文献
1) Hamatani Y, Iguchi M, Ikeyama Y, et al. Comprehensive symptom assessment using Integrated Palliative care Outcome Scale in hospitalized heart failure patients. ESC Heart Fail. 2022 ; 9 : 1963-75.
PubMed
2) Tsutsui H, Isobe M, Ito H, et al. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure-Digest Version. Circ J. 2019 ; 83 : 2084-184.
PubMed
3) Pratama NR, Anastasia ES, Wardhani NP, et al. Clinical outcomes of opioid administration in acute and chronic heart failure : A meta-analysis. Diabetes Metab Syndr. 2022 ; 16 : 102636.
PubMed
4) McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 : 3599-726.
PubMed
5) Nordgren L, Sorensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J Cardiovasc Nurs. 2003 ; 2 : 213-7.
PubMed
6) Kawaguchi J, Hamatani Y, Hirayama A, et al. Experience of morphine therapy for refractory dyspnea as palliative care in advanced heart failure patients. J Cardiol. 2020 ; 75 : 682-8.
PubMed
7) Murakami M. Opioids for relief of dyspnea immediately before death in patients with noncancer disease : A case series study. Am J Hosp Palliat Care. 2019 ; 36 : 734-9.
PubMed
8) Yamaguchi T, Goya S, Kohara H, et al. Treatment recommendations for respiratory symptoms in cancer patients : Clinical Guidelines from the Japanese Society for Palliative Medicine. J Palliat Med. 2016 ; 19 : 925-35.
 
9) Sobanski PZ, Alt-Epping B, Currow DC, et al. Palliative care for people living with heart failure : European Association for Palliative Care Task Force expert position statement. Cardiovasc Res. 2020 ; 116 : 12-27.
PubMed
10) Anzai T, Sato T, Fukumoto Y, et al. JCS/JHFS 2021 Statement on Palliative Care in Cardiovascular Diseases. Circ J. 2021 ; 85 : 695-757.
PubMed
11) Tanaka M, Maeba H, Senoo T, et al. Efficacy of oxycodone for dyspnea in end-stage heart failure with renal insufficiency. Intern Med. 2018 ; 57 : 53-7.
PubMed
12) Ohmori T, Mizuno A, Kawai F, et al. Morphine use for heart failure patients with renal insufficiency. J Palliat Med. 2019 ; 22 : 617-8.
PubMed
13) Gotou M, Suzuki A, Shiga T, et al. Adverse drug reactions in Japanese patients with end-stage heart failure receiving continuous morphine infusion : A single-center retrospective cohort study. Drugs Real World Outcomes. 2022 ; 9 : 1-8.
PubMed
14) Hughes CG, Mailloux PT, Devlin JW, et al. Dexmedetomidine or propofol for sedation in mechanically ventilated adults with sepsis. N Engl J Med. 2021 ; 384 : 1424-36.
PubMed
15) Kuragaichi T, Kurozumi Y, Ohishi S, et al. Nationwide survey of palliative care for patients with heart failure in Japan. Circ J. 2018 ; 82 : 1336-43.
PubMed
16) Hamatani Y, Nakai E, Nakamura E, et al. Survey of palliative sedation at end of life in terminally ill heart failure patients-A single-center experience of 5-year follow-up. Circ J. 2019 ; 83 : 1607-11.
PubMed
17) Hamatani Y, Iguchi M, Ikeyama Y, et al. Prevalence, temporal change, and determinants of anxiety and depression in hospitalized patients with heart failure. J Card Fail. 2022 ; 28 : 181-90.
PubMed
18) Mizuno A, Miyashita M, Kohno T, et al. Quality indicators of palliative care for acute cardiovascular diseases. J Cardiol. 2020 ; 76 : 177-83.
PubMed
19) Hamatani Y, Takada Y, Miyamoto Y, et al. Development and practical test of quality indicators for palliative care in patients with chronic heart failure. Circ J. 2020 ; 84 : 584-91.
PubMed
20) Shibata T, Oishi S, Mizuno A, et al. Evaluation of the effectiveness of the physician education program on primary palliative care in heart failure. PLoSOne. 2022 ; 17 : e0263523.
 

15章 成人先天性心疾患患者の心不全

P.309 掲載の参考文献
1) Shiina Y, Toyoda T, Kawasoe Y, et al. Prevalence of adult patients with congenital heart disease in Japan. Int J Cardiol. 2011 ; 146 : 13-6.
PubMed
2) Stout KK, Broberg CS, Book WM, et al. Chronic heart failure in congenital heart disease : A scientific statement from the American Heart Association. Circulation. 2016 ; 133 : 770-801.
PubMed
3) Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease : comparative severity, correlates, and prognostic implication. Circulation. 2005 ; 112 : 828-35.
PubMed
4) Hoeper MM, Galie N, Murali S, et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002 ; 165 : 341-4.
PubMed
5) Tobler D, Greutmann M, Colman JM, et al. End-of-life care in hospitalized adults with complex congenital heart disease : care delayed, care denied. Palliat Med. 2012 ; 26 : 72-9.
PubMed
6) Ludmir J, Steiner JM, Wong HN, et al. AAHPM Research Committee Writing Group. Palliative care opportunities among adults with congenital heart disease-A systematic review. J Pain Symptom Manage. 2019 ; 58 : 891-8.
PubMed
7) Stout KK, Broberg CS, Book WM, et al. American Heart Association Council on Clinical Cardiology, Council on Functional Genomics and Translational Biology, and Council on Cardiovascular Radiology and Imaging. Chronic heart failure in congenital heart disease : A scientific statement from the American Heart Association. Circulation. 2016 ; 133 : 770-801.
PubMed
8) Zandstra TE, Nederend M, Jongbloed MRM, et al. Sacubitril/valsartan in the treatment of systemic right ventricular failure. Heart. 2021 ; 107 : 1725-30.
PubMed
9) Maurer SJ, Pujol Salvador C, Schiele S, et al. Sacubitril/valsartan for heart failure in adults with complex congenital heart disease. Int J Cardiol. 2020 ; 300 : 137-40.
PubMed
10) Egorova AD, Nederend M, Tops LF, et al. The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure. ESC Heart Fail. 2022 ; 9 : 2007-12.
PubMed
11) Saef J, Sundaravel S, Ortega-Legaspi J, et al. Safety and treatment experience with sodium/glucose cotransporter-2 inhibitors in adult patients with congenital heart disease. J Card Fail. 2023 : S1071-9164 (23) 00104-5.
 

16章 心不全における免疫抑制療法

P.319 掲載の参考文献
1) 永井利幸, 猪又孝元, 河野隆志, 他. 2023年改訂版 心筋炎の診断・治療に関するガイドライン. 日本循環器学会. 2023.
 
2) Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management of fulminant myocarditis : A scientific statement from the American Heart Association. Circulation. 2020 ; 141 : e69-92.
PubMed
3) Basso C. Myocarditis. N Engl J Med. 2022 ; 387 : 1488-500.
PubMed
4) Ammirati E, Frigerio M, Adler ED, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy : An expert consensus document. Circ Hear Fail. 2020 ; 13 : E007405.
 
5) Kanaoka K, Onoue K, Terasaki S, et al. Features and outcomes of histologically proven myocarditis with fulminant presentation. Circulation. 2022 ; 146 : 1425-33.
PubMed
6) Okura Y, Dec GW, Hare JM, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol. 2003 ; 41 : 322-9.
PubMed
7) Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis-Natural history and treatment. N Engl J Med. 1997 ; 336 : 1860-6.
PubMed
8) Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Hear Fail. 2013 ; 6 : 15-22.
 
9) Bang V, Ganatra S, Shah SP, et al. Management of patients with giant cell myocarditis : JACC review topic of the week. J Am Coll Cardiol. 2021 ; 77 : 1122-34.
 
10) Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : ASCO Guideline Update. J Clin Oncol. 2021 ; 39 : 4073-126.
PubMed
11) Zhang L, Zlotoff DA, Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-Associated myocarditis. Circulation. 2020 ; 141 : 2031-4.
PubMed
12) Zhang L, Reynolds KL, Lyon AR, et al. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity. JACC Cardio Oncol. 2021 ; 3 ; 35-47.
 
13) Kishimoto C, Shioji K, Hashimoto T, et al. Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy : analysis of leukocyte balance. Heart Vessels. 2014 ; 29 : 336-42.
PubMed
14) Isogai T, Yasunaga H, Matsui H, et al. Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality : propensity score analyses. J Card Fail. 2015 ; 21 : 391-7.
PubMed
15) Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy : The TIMIC study. Eur Heart J. 2009 ; 30 : 1995-2002.
 
16) Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy : two-year follow-up results. Circulation. 2001 ; 104 : 39-45.
PubMed
17) 寺崎文夫, 我妻安良太, 安斎俊久, 他. 2016年度版 心臓サルコイドーシスの診療ガイドライン. 2016. p.1-75.
 
18) Hashimura M, Ikeda Y, Koitabashi T, et al. Cardiac sarcoidosis presenting with cardiogenic shock successfully recovered by Impella and corticosteroid pulse therapy : a case report. Eur Heart J. Case reports 2023 Feb ; 7 (2).
 
19) Panettieri RA, Schaafsma D, Amrani Y, et al. Non-genomic effects of glucocorticoids : An updated view. Trends Pharmacol Sci. 2019 ; 40 : 38-49.
PubMed
20) Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases : an update on the mechanisms of action. Arthritis Rheum. 2004 ; 50 : 3408-17.
PubMed
21) Fragoulis GE, Nikiphorou E, Dey M, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2022 ; ard-2022-223335.
PubMed
22) Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989 ; 11 : 954-63.
PubMed
23) Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009 ; 68 : 1119-24.
PubMed
24) Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2017 ; 69 : 1095-110.
PubMed
25) Kolluri N, Elwazir MY, Rosenbaum AN, et al. Effect of corticosteroid therapy in patients with cardiac sarcoidosis on frequency of venous thromboembolism. Am J Cardiol. 2021 ; 149 : 112-8.
PubMed
26) Rosenthal DG, Parwani P, Murray TO, et al. Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc. 2019 ; 8 : e010952.
PubMed
27) Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021 ; 374 : n1380.
PubMed
28) Bakker ALM, Mathijssen H, Azzahhafi J, et al. Effectiveness and safety of infliximab in cardiac sarcoidosis. Int J Cardiol. 2021 ; 330 : 179-85.
PubMed
29) Nagaoka S, Katayama K, Kasama T, et al. Weekly split-dose regimen for oral methotrexate reduced polyglutamation in red blood cells in patients with rheumatoid arthritis compared with single-dose regimen : Results from a multicentered randomized control trial. Int J Rheum Dis. 2020 ; 23 : 1328-36.
PubMed

17章 心不全治療薬の投与量と薬物動態

P.325 掲載の参考文献
1) Fukuda K, Date H, Doi S, et al. Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017). Circ J. 2019 ; 83 : 842-945.
PubMed
2) Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022 ; 43 : 3618-731.
 
3) Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002 ; 85 : 195-7.
PubMed
4) Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction : a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013 ; 128 : 502-11.
PubMed
5) Vachiery JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018 ; 51 : 1701886.
 
6) Douschan P, Kovacs G, Avian A, et al. Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med. 2018 ; 197 : 509-16.
PubMed
7) Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects : a systematic review. Eur Respir J. 2009 ; 34 : 888-94.
PubMed
8) Vachiery JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019 ; 53 : 1801897.
PubMed

書評

最近チェックした商品履歴

Loading...